Clinical development of mycophenolate mofetil in multiple sclerosis

This month's Spotlight on... focuses on the clinical development of the immunomodulatory agent mycophenolate mofetil as an adjunctive therapy for multiple sclerosis. Mycophenolate mofetil (MMF) is postulated to target several mechanisms underlying the progression of this autoimmune disease, and clinical studies to date have provided evidence for treatment-associated clinical improvements or a halt in disease progression. Ongoing phase II/III clinical trials are investigating the efficacy and safety of MMF as both a monotherapy or in combination with interferon beta-1a.